The immunosuppressive effects of glucocorticoids (GCs) are well-established. However, whether the net effect of GC-elicited alterations in immune function is sufficient to influence a clinically relevant outcome in healthy adults has yet to be shown. The aim of the present study was to investigate whether interindividual differences in basal salivary cortisol production are associated with increased risk and severity of infection and subsequent illness following experimental exposure to a virus that causes the common cold. The present analyses combine archival data from three viral-challenge studies. Participants were 608 healthy adults, aged 18 to 55 years (49.2% female; 65.8% white), who each completed a three-day saliva collection protocol; was subsequently exposed to a virus that causes the common cold; and monitored for 5 days for objective signs of infection (presence of challenge virus in nasal secretions) and clinical illness (mucus weight, mucociliary clearance time). Basal cortisol production (operationalized as the calculated area-under-the-curve averaged across the 3 days) showed a graded association with infection risk, with those producing higher levels of cortisol being at greater risk. Cortisol also showed a continuous association with duration of viral shedding, an indicator of viral replication and continuing infection, such that higher cortisol concentrations predicted more days of shedding. Cortisol was not, however, related to severity of objective illness. These findings are the first to demonstrate in healthy adults an association between basal cortisol production and an objectively measured and clinically relevant infectious disease outcome.
Introduction
Chronic dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis has been implicated in the pathogenesis of various forms of immune-related disease. Findings from comparative animal research, as well as from human research conducted in vitro, suggest that stress-related elevations in circulating glucocorticoid (GC) hormones may suppress host resistance to infectious disease via downregulatory effects on both innate and adaptive immunity (Bailey et al., 2003; Sheridan et al., 1998) . Effects of chronically elevated GCs on natural immunity include inhibition of lymphocyte trafficking during the initial phases of viral infection (e.g., Hermann et al., 1995; Tseng et al., 2005) as well as suppressed synthesis of pro-inflammatory cytokines by macrophages (Brattsand and Linden, 1996) . In regard to acquired immunity, GCs have been shown to have modulatory effects on T-helper (Th) activity, simultaneously facilitating a Th2 pattern of cytokine production while inhibiting the production of Th1 cytokines (Elenkov and Chrousos, 1999) . One consequence of this shift to a predominantly humoral immune response is attenuation of cell-mediated defense against viral infection (Gern et al., 2000) .
The clinical relevance of these in vitro and ex vivo findings from comparative laboratory research has been demonstrated in populations of patients with pathologically elevated levels of circulating GCs. In these populations, hypercortisolemia-whether induced endogenously (i.e., spontaneous Cushing syndrome) or from exogenous administration of therapeutic corticosteroids-is associated with increased risk for infection by opportunistic pathogens (Lionakis and Kontoyiannis, 2003; Sarlis et al., 2000; Stuck et al., 1989) . Furthermore, the severity of established infections has been found to increase in a dose-response manner with the degree of hypercortisolemia (Aucott, 1994; Graham and Tucker, 1984) . Even relatively short-term exposure to corticosteroids (days rather than weeks, months, or years) has been found to influence the course of http://dx.doi.org/10.1016/j.bbi.2016.01.013 0889-1591/Ó 2016 Elsevier Inc. All rights reserved.
